FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313367888> ?p ?o ?g. }

• W4313367888 endingPage "100720" @default.
• W4313367888 startingPage "100720" @default.
• W4313367888 abstract "Non-small cell lung cancer (NSCLC) is a leading cause of cancer death worldwide. Ramucirumab plus docetaxel became one of the available options for subsequent treatment in NSCLC after REVEL study. In addition, immune-checkpoint inhibitors (ICIs) became standard of treatment for NSCLC. Combining ICIs with anti-vascular endothelial growth factor blockade is one of many tries to overcome the resistance. We present our real-world data of ramucirumab plus docetaxel compared with docetaxel after ICIs in stage IV NSCLC patients. We retrospectively collected clinicopathologic data of NSCLC patients who were treated with ramucirumab plus docetaxel or docetaxel for second to fourth line of treatment after ICIs from 1st January 2019 to 31th October 2021 in Samsung Medical Center. After patients with EGFR, ALK or ROS1 mutations were excluded, 38 patients in ramucirumab/docetaxel group and 183 patients in docetaxel group were included in the analysis. Primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and overall response rate (ORR). Variables of age, treatment line were significantly different between two groups. Ramucirumab/docetaxel showed significantly better PFS than docetaxel alone after ICIs (p = 0.012) in this analysis. Hazard ratio was 0.59 (95% confidence interval 0.37 – 0.96). Median PFS was 6 months in ramucirumab/ docetaxel group, and 2 months in docetaxel group. In multivariable analysis for PFS with cox proportional hazard regression, only treatment group and histology showed significant differences. Ramucirumab/ docetaxel group had a significantly better response than docetaxel group (p = 0.019). 14 (36.8%) and 47 (25.7%) in ramucirumab/docetaxel group and docetaxel group each achieved partial response. Only one patient who were treated with docetaxel showed complete response among all patients. 18 (47.4%) patients in ramucirumab/docetaxel group and 68 (37.2%) patients in docetaxel group showed stable disease as a best response. However, there was no significant benefit regarding OS in this analysis (p = 0.45) and even docetaxel tends to prolong OS than ramucirumab/docetaxel. Ramucirumab plus docetaxel showed significantly higher PFS compared with docetaxel alone after ICIs in stage IV NSCLC in this analysis of real-world data. ORR was also significantly higher in ramucirumab/docetaxel group than docetaxel alone group. However, OS was not significantly different between two groups in this study." @default.
• W4313367888 created "2023-01-06" @default.
• W4313367888 creator A5001914197 @default.
• W4313367888 creator A5025430914 @default.
• W4313367888 creator A5032508569 @default.
• W4313367888 creator A5052986191 @default.
• W4313367888 creator A5059712837 @default.
• W4313367888 creator A5078299820 @default.
• W4313367888 creator A5078752460 @default.
• W4313367888 date "2022-12-01" @default.
• W4313367888 modified "2023-09-26" @default.
• W4313367888 title "PP225 Real-world data of ramucirumab plus docetaxel compared with docetaxel after immune-checkpoint inhibitors in stage IV non-small cell lung cancer patients" @default.
• W4313367888 doi "https://doi.org/10.1016/j.esmoop.2022.100720" @default.
• W4313367888 hasPublicationYear "2022" @default.
• W4313367888 type Work @default.
• W4313367888 citedByCount "0" @default.
• W4313367888 crossrefType "journal-article" @default.
• W4313367888 hasAuthorship W4313367888A5001914197 @default.
• W4313367888 hasAuthorship W4313367888A5025430914 @default.
• W4313367888 hasAuthorship W4313367888A5032508569 @default.
• W4313367888 hasAuthorship W4313367888A5052986191 @default.
• W4313367888 hasAuthorship W4313367888A5059712837 @default.
• W4313367888 hasAuthorship W4313367888A5078299820 @default.
• W4313367888 hasAuthorship W4313367888A5078752460 @default.
• W4313367888 hasBestOaLocation W43133678881 @default.
• W4313367888 hasConcept C121608353 @default.
• W4313367888 hasConcept C126322002 @default.
• W4313367888 hasConcept C143998085 @default.
• W4313367888 hasConcept C207103383 @default.
• W4313367888 hasConcept C2776256026 @default.
• W4313367888 hasConcept C2779551604 @default.
• W4313367888 hasConcept C2781190966 @default.
• W4313367888 hasConcept C44249647 @default.
• W4313367888 hasConcept C71924100 @default.
• W4313367888 hasConceptScore W4313367888C121608353 @default.
• W4313367888 hasConceptScore W4313367888C126322002 @default.
• W4313367888 hasConceptScore W4313367888C143998085 @default.
• W4313367888 hasConceptScore W4313367888C207103383 @default.
• W4313367888 hasConceptScore W4313367888C2776256026 @default.
• W4313367888 hasConceptScore W4313367888C2779551604 @default.
• W4313367888 hasConceptScore W4313367888C2781190966 @default.
• W4313367888 hasConceptScore W4313367888C44249647 @default.
• W4313367888 hasConceptScore W4313367888C71924100 @default.
• W4313367888 hasIssue "6" @default.
• W4313367888 hasLocation W43133678881 @default.
• W4313367888 hasOpenAccess W4313367888 @default.
• W4313367888 hasPrimaryLocation W43133678881 @default.
• W4313367888 hasRelatedWork W1915401051 @default.
• W4313367888 hasRelatedWork W2530066279 @default.
• W4313367888 hasRelatedWork W2543282426 @default.
• W4313367888 hasRelatedWork W2766624957 @default.
• W4313367888 hasRelatedWork W2949761024 @default.
• W4313367888 hasRelatedWork W3041235120 @default.
• W4313367888 hasRelatedWork W3136784172 @default.
• W4313367888 hasRelatedWork W3187094417 @default.
• W4313367888 hasRelatedWork W4328112160 @default.
• W4313367888 hasRelatedWork W4386421669 @default.
• W4313367888 hasVolume "7" @default.
• W4313367888 isParatext "false" @default.
• W4313367888 isRetracted "false" @default.
• W4313367888 workType "article" @default.